Recent Updates
Recently added Catalysts
IRON

Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024

Wednesday, March 6, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024
Price reaction · baseline $69.04 (2024-03-05 close) · hit after-hours · clean, no other IRON news in the window
day 0 close · peak
-4.3%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+45%
120-day peak, hindsight
Typical move
3.9%
average across 7 past catalysts
Cash runway
~48 mo
Minimal dilution risk
Lead asset
DISC-0974
Phase 2 · Inflammatory Bowel Disease (IBD)

Full Press Release Details

Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024.
ShareAdd on Google
Tags: IRON Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Mar 6, 2024

Biotech snapshot

Cash runway
$718M liquidity · $15M/mo burn
~48 mo
Minimal dilution risk
Lead asset
DISC-0974Phase 2
Inflammatory Bowel Disease (IBD) →

Catalyst track record

+45%
best trade around IRON's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for IRON.

See every catalyst's timing & PoA →